HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives $20.88 Consensus Target Price from Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been assigned a consensus recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $20.8750.

Several research firms recently issued reports on HCM. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a report on Monday, January 19th. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th.

Institutional Trading of HUTCHMED

Several hedge funds have recently modified their holdings of HCM. Blue Trust Inc. grew its stake in HUTCHMED by 131.5% during the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after purchasing an additional 4,378 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its position in shares of HUTCHMED by 23.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock worth $233,000 after buying an additional 2,916 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares during the period. Bank of America Corp DE raised its holdings in HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after acquiring an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in HUTCHMED by 34.2% in the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after acquiring an additional 5,538 shares in the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.

HUTCHMED Trading Up 1.0%

HUTCHMED stock opened at $15.11 on Thursday. The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average price of $14.38 and a 200 day moving average price of $15.24. HUTCHMED has a fifty-two week low of $11.51 and a fifty-two week high of $19.50.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.